title: [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
abstract: Calcitriol deficiency and phosphorus retention are mechanisms involved in the pathogenesis of renal hyperparathyroidism. The aim of this study was to evaluate the effect of dietary phosphorus restriction versus calcium carbonate treatment for one month on PTH and calcitriol levels in patients with mild renal failure. We studied two groups of patients: Group I: 21 patients (14M/7F); mean age 61 years old; mean glomerular filtration rate 51 ml/min. Their diet contained phosphorus 700 mg/day. Group II: 30 patients (21M/9F); mean age 58; mean glomerular rate 56 ml/min. They were divided in two subgroups: 18 patients treated with calcium carbonate 2.5 g/day and 12 patients with 5 g/day. Serum PTH, calcitriol, 25(OH)D3, calcium, phosphorus and urinary excretion of calcium and phosphorus were measured before and after a 30 day period. The low phosphorus diet (Group I) resulted in a significant decrease in PTH levels (81.3 +/- 35 vs 71 +/- 39 pg/ml, p < 0.05) and significant increase in calcitriol levels (22.4 +/- 4.4 vs 33.4 +/- 7.5 pg/ml, p < 0.05). In our study calcium carbonate treatment (Group II) had no effect on PTH and calcitriol levels.
authors.affiliation: Servicio de Nefrología, Hospital Universitario Virgen Macarena Avda. Dr. Fedriani, s/n 41071 Sevilla.
authors.forename: N
authors.initials: N
authors.lastname: Aresté
authors.forename: J
authors.initials: J
authors.lastname: Amor
authors.forename: T
authors.initials: T
authors.lastname: Cambil
authors.forename: M
authors.initials: M
authors.lastname: Salgueira
authors.forename: R
authors.initials: R
authors.lastname: Sánchez-Palencia
authors.forename: C
authors.initials: C
authors.lastname: Páez
authors.forename: O
authors.initials: O
authors.lastname: Gómez
authors.forename: A
authors.initials: A
authors.lastname: Palma
mesh_terms: D000368:Aged; D002112:Calcifediol / Q000097:blood; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000627:therapeutic use*; D002136:Calcium, Dietary / Q000008:administration & dosage; D002614:Chelating Agents / Q000627:therapeutic use*; D015913:Chelation Therapy; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000178:diet therapy / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D016226:Phosphorus, Dietary / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D002136:Calcium, Dietary; D002614:Chelating Agents; D010281:Parathyroid Hormone; D016226:Phosphorus, Dietary; D010758:Phosphorus; D003404:Creatinine; D002117:Calcitriol; D002119:Calcium Carbonate; D002112:Calcifediol; D002118:Calcium